{"nctId":"NCT00626431","briefTitle":"A Study of Leuprolide to Treat Prostate Cancer","startDateStruct":{"date":"2008-02"},"conditions":["Prostate Cancer"],"count":310,"armGroups":[{"label":"Leuprolide acetate - Formulation A","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprolide acetate - Formulation A"]},{"label":"Leuprolide acetate - Formulation B","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprolide acetate - Formulation B"]}],"interventions":[{"name":"Leuprolide acetate - Formulation A","otherNames":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"]},{"name":"Leuprolide acetate - Formulation B","otherNames":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Voluntarily sign an IRB-approved informed consent form and any required privacy statement/authorization form.\n* Pre-trial serum testosterone level \\>150 ng/dL.\n* Histologically-confirmed prostatic adenocarcinoma in Jewett Clinical Stage A2, B, C or D and TNM\\* classification cT1b-4, N: any, M: any.\n\n  \\*Tumor/Nodes/Metastases\n* Subjects with a rising PSA following radical prostatectomy defined as an increase of 0.2 ng/mL from the previous test on two consecutive testings or rising PSA following prostate irradiation using Phoenix Definition of a rise of greater than or equal to 2.0 ng/mL above the nadir.\n* Prostate cancer and general clinical status is sufficient to warrant at least 48 weeks of continuous androgen deprivation treatment, without concomitant antiandrogen treatment.\n* Eastern Cooperative Oncology Group (ECOG) Performance status grades 0,1,or 2 at the time of pre-trial screening.\n* Life expectancy of at least 18 months.\n* Subjects with serum creatinine ≤1.9 mg/dL, bilirubin ≤2.0 mg/dL (unless Gilbert's syndrome with normal AST, ALT); AST and ALT ≤2.5 times the upper limit of normal.\n\nExclusion Criteria:\n\n* Requires additional treatment including radical prostatectomy, radiotherapy or cryotherapy of local disease.\n* Historical, clinical, or radiographic evidence of central nervous system metastases, including spinal cord metastasis.\n* Clinical evidence of urinary tract obstruction.\n* History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.\n* History of clinical hypogonadism.\n* Current malignancy or history of malignancy except for prostate cancer or basal or squamous cell carcinoma of the skin.\n* Clinical or laboratory evidence of any severe underlying disease state (excluding prostate cancer) that would place subjects in additional jeopardy by participating in this trial.\n* Hypersensitivity to leuprolide, polylactic acid, or any excipient of the drug.\n* Incomplete recovery from the effects of any major surgery.\n* History of receiving of the following prostate cancer therapies within 8 weeks prior to the Screening Visit: chemotherapy, immunotherapy, antiandrogen, radiation therapy, cryotherapy, strontium, or biological response modifiers.\n* History of prostatic surgery within 4 weeks prior to the Screening Visit.\n* Received hormonal therapy, including GnRH analogs (less than or equal to 6 month depot administration), estrogen, Megace and phytotherapy, within 32 weeks prior to the Screening Visit and during the trial.\n* Alternative medical therapies which have an estrogenic, androgenic, or antiandrogenic effect (including phyto-estrogens and phyto-androgens) within 12 weeks prior to the Screening Visit and during the trial.\n* Requires the chronic use of systemic corticosteroids and anticonvulsants that may affect bone loss such as carbamazepine, phenobarbital, phenytoin, valproic acid or primidone.\n* May require antiandrogen, immuno-, or surgical therapy for prostate cancer during the trial.\n* History of alcoholism or consumes \\>14 alcoholic beverages per week or illicit drug abuse within 12 months prior to screening.\n* Received therapy with a GnRH analog (1 year implant) within 60 weeks prior to the Screening Visit.\n* Received therapy with finasteride or ketoconazole within 1 week prior to the Screening Visit; dutasteride within 25 weeks prior to the Screening Visit.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.","description":"The percentage of subjects with testosterone suppression (\\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":"2.05"}]}]}]},{"type":"SECONDARY","title":"Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population","description":"Baseline was the last measurement before the first dose of Formulation A. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"432.9","spread":"14.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"613.1","spread":"21.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"468.2","spread":"16.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.1","spread":"7.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"1.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"4.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"3.67"}]}]}]},{"type":"SECONDARY","title":"Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population","description":"Baseline was the last measurement before the first dose of Formulation B. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"414.0","spread":"14.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"578.0","spread":"20.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"466.9","spread":"17.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.4","spread":"7.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":"3.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"2.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"1.87"}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population","description":"The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population","description":"The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"1.43"}]}]}]},{"type":"PRIMARY","title":"Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted","description":"The adjusted percentage of subjects with testosterone suppression (\\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. The primary efficacy analysis was adjusted to censor subjects who received an anti-androgen at the last testosterone measurement before use of the anti-androgen. One additional subject was censored because of a laboratory error, at the last measurement before the error. The adjusted 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population","description":"The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population","description":"The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population","description":"PSA levels were measured at baseline and each treatment visit for Formulation A. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"11.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":"12.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.51"}]}]}]},{"type":"SECONDARY","title":"Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population","description":"PSA levels were measured at baseline and each treatment visit for Formulation B. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":"3.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":"4.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"2.75"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned","description":"The percentage of subjects with testosterone suppression (\\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":151},"commonTop":["hot flush","injection site pain","arthralgia","fatigue","constipation"]}}}